Neurogenesis, Myelination, and Circuitry: The Case for a Distributed Therapeutic Regimen in Down Syndrome.
Tarik F Haydar
PMID 32058811WHAT IT FOUND
This paper proposes a biological timeline for Down syndrome deficits, suggesting that different therapies might be needed at different life stages.
It is a theoretical argument with no clinical data, so it offers no guidance on current treatment.
What this paper is
This is a theoretical review discussing the biological mechanisms of Down syndrome, such as neurogenesis and myelination, and proposing a conceptual framework for future therapies. It reports no patient data, no clinical trials, and no outcomes, so there is nothing here to change your practice on.
The easy way to misread this
Do not interpret the proposed 'distributed therapeutic regimen' as a current clinical protocol. The paper describes biological mechanisms and hypothetical future strategies, not interventions that have been tested or are available for use.